Stelios Papadopoulos, Director at Regulus Therapeutics Inc. (RGLS), bought 800,000 shares at $1.33 ($1.1M) on 2018-11-15, disclosed to the SEC on 2018-11-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.33 | 200,000 | $266K | 24.3% |
| 2 | $1.38 | 300,000 | $414K | 37.8% |
| 3 | $1.38 | 300,000 | $414K | 37.8% |
| Total | $1.37 avg | 800,000 | $1.1M | 100% |
| Filing → |
| EXEL | SELL | 2024-05-22 | $240K | — | Filing → |
| EXEL | SELL | 2022-02-24 | $3.3M | — | Filing → |
| EXEL | SELL | 2021-05-13 | $911K | — | Filing → |